BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11960290)

  • 1. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.
    Schirrmann T; Pecher G
    Leuk Res; 2005 Mar; 29(3):301-6. PubMed ID: 15661266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells.
    Sasaki T; Ikeda H; Sato M; Ohkuri T; Abe H; Kuroki M; Onodera M; Miyamoto M; Kondo S; Nishimura T
    Cancer Sci; 2006 Sep; 97(9):920-7. PubMed ID: 16856879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
    Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
    Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo.
    Biglari A; Southgate TD; Fairbairn LJ; Gilham DE
    Gene Ther; 2006 Apr; 13(7):602-10. PubMed ID: 16397508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
    Moritz D; Groner B
    Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
    Shibaguchi H; Arakawa F; Imakiire T; Kuroki M; Kuroki M
    Anticancer Res; 2003; 23(6a):4383-8. PubMed ID: 14666725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.
    Roberts MR; Cooke KS; Tran AC; Smith KA; Lin WY; Wang M; Dull TJ; Farson D; Zsebo KM; Finer MH
    J Immunol; 1998 Jul; 161(1):375-84. PubMed ID: 9647246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
    Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
    Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
    Altenschmidt U; Klundt E; Groner B
    J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
    Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
    Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [T lymphocytes with chimeric receptor induce carcinoembryonic antigen-positive specific gastric carcinoma cells apoptosis].
    Xu HY; Xu L; Gao JH; Li KZ; Dou KF
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1053-7. PubMed ID: 17672971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
    Tsang KY; Zhu M; Nieroda CA; Correale P; Zaremba S; Hamilton JM; Cole D; Lam C; Schlom J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2439-49. PubMed ID: 9815645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.